Anhui Fengyuan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2019
August 28, 2019 at 07:04 pm
Share
Anhui Fengyuan Pharmaceutical Co., Ltd. announced earnings results for the half year ended June 30, 2019. For the half year, the company announced sales was CNY 1,567.862 million compared to CNY 1,475.406 million a year ago. Operating income was CNY 79.905 million compared to CNY 59.306 million a year ago. Net income was CNY 56.566 million compared to CNY 38.081 million a year ago. Basic earnings per share from continuing operations was CNY 0.1812 compared to CNY 0.1201 a year ago. Sales was CNY 3,687.931 million compared to CNY 2,728.166 million a year ago. Operating income was CNY 2,708.494 million compared to CNY 2,464.237 million a year ago. Net income was CNY 2,301.220 million compared to CNY 2,011.911 million a year ago. Basic earnings per share from continuing operations was CNY 0.3725 compared to CNY 0.3256 a year ago. Diluted earnings per share from continuing operations was CNY 0.342 compared to CNY 0.3256 a year ago.
ANHUI FENGYUAN PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research and development, manufacture and distribution of biological medicines, chemical synthetic medicines and Chinese medicines. The Company's products mainly include antipyretic and analgesic, women and children, the nervous system, cardiovascular, urinary system, nutrition, antibiotics and active ingredient and other products. The Company is also engaged in the retailing and wholesale of drugs. The Company conducts its businesses mainly in domestic markets, with Anhui province as its main market.
ANHUI FENGYUAN PHARMACEUTICAL CO., LTD. 
